A Novel Chordoma Xenograft Allows In Vivo Drug Testing and Reveals the Importance of NF-κB Signaling in Chordoma Biology
Open Access
- 6 November 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (11), e79950
- https://doi.org/10.1371/journal.pone.0079950
Abstract
Chordoma is a rare primary bone malignancy that arises in the skull base, spine and sacrum and originates from remnants of the notochord. These tumors are typically resistant to conventional chemotherapy, and to date there are no FDA-approved agents to treat chordoma. The lack of in vivo models of chordoma has impeded the development of new therapies for this tumor. Primary tumor from a sacral chordoma was xenografted into NOD/SCID/IL-2R γ-null mice. The xenograft is serially transplantable and was characterized by both gene expression analysis and whole genome SNP genotyping. The NIH Chemical Genomics Center performed high-throughput screening of 2,816 compounds using two established chordoma cell lines, U-CH1 and U-CH2B. The screen yielded several compounds that showed activity and two, sunitinib and bortezomib, were tested in the xenograft. Both agents slowed the growth of the xenograft tumor. Sensitivity to an inhibitor of IκB, as well as inhibition of an NF-κB gene expression signature demonstrated the importance of NF-κB signaling for chordoma growth. This serially transplantable chordoma xenograft is thus a practical model to study chordomas and perform in vivo preclinical drug testing.This publication has 29 references indexed in Scilit:
- An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordomaThe Journal of Pathology, 2012
- Frequent activation of EGFR in advanced chordomasClinical Sarcoma Research, 2011
- The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical GenomicsScience Translational Medicine, 2011
- Regulation of cancer germline antigen gene expression: implications for cancer immunotherapyFuture Oncology, 2010
- Identification of known drugs that act as inhibitors of NF-κB signaling and their mechanism of actionBiochemical Pharmacology, 2010
- Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomasNeuro-Oncology, 2010
- T (brachyury) gene duplication confers major susceptibility to familial chordomaNature Genetics, 2009
- Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor SarcomasJournal of Clinical Oncology, 2009
- Activated TNF-α/NF-κB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout miceProceedings of the National Academy of Sciences of the United States of America, 2009
- A New IκB Kinase β Inhibitor Prevents Human Breast Cancer Progression through Negative Regulation of Cell Cycle TransitionCancer Research, 2006